XIV Spanish Drug Discovery Network Meeting (Granada, 24-25th November)
On November 24-25th, Domingo Gargallo-Viola chaired the session on Antimicrobial Resistance and New Antibiotics in the XIV Spanish Drug Discovery Network Meeting that took place in Granada. In addition to Domingo Gargallo-Viola, Concepcion Gonzalez-Bello (University Santiago de Compostela), Sergio Lociuro (CSO Bioversys), and Rafael Canton Moreno (Hospital Ramon y Cajal, Madrid), gave different talks on one of the biggest global health challenges, […]
ABAC Therapeutics in collaboration with FNDR and Peptris lead an international project to develop new antibiotics against gram-negative bacteria
ABAC Therapeutics, together with the artificial intelligence (AI) company, Peptris, and the Foundation for Neglected Disease Research (FNDR), with scientific support from Medicines for Malaria Venture (MMV), leads an international project to optimize a new chemical structure that has shown effectiveness against Gram-negative bacteria, the greatest current threat to public health. In recent decades, there […]
Scientists search for molecules against antibiotic-resistant bacteria
Researchers from the Universitat Politècncia de Catalunya (UPC) and ABAC Therapeutics collaborate to develop new compounds and molecules designed to selectively attack bacteria resistant to current antibiotics. The new drugs will be respectful of the human bacterial flora making possible to combat the resistance of some of these pathogens «using an innovative approach» based on […]
68 Top Life Science Startups and Companies in Spain (2021)
We are happy to see that ABAC has been selected as one the top 68 life science startups and companies in 2021 in Spain. The startups and companies have been selected for their exceptional performances in the following categories: innovation, growth, management and societal impact.
The overlooked pandemic of antimicrobial resistance
An estimated 1.2 million people died from antibiotic-resistant bacterial infections in 2019, accounting for more deaths than from HIV/AIDS or malaria. AMR is the global health threat we cannot afford to ignore. A new comprehensive analysis reveals the scale of antimicrobial resistance (AMR), now a leading cause of death worldwide.
R&D for precision medicine in infectious diseases, an investment with social impact
ABAC Therapeutics was founded in 2014 with the aim of discovering and developing new antibacterial agents with a new perspective focused on precision medicine. The research is focused on the discovery of antibiotics with specific activity against pathogenic bacteria that cause infections in humans. As Domingo Gargallo-Viola, co-founder and CEO of the company says, “We […]
TV3. 30 minuts: «The end of antibiotics»
Why are antibiotics no longer effective? How come superbugs have become so strong? The misuse and abuse of antibiotics has led bacteria to learn to defend themselves and become resistant. In 2050 there could be more deaths from “superbugs” than from cancer. Ramón Morales was 31 years old when he died from an infection by […]
LA SEXTA. Equipo de investigación: «The invisible enemy»
The space presented by Gloria Serra deals with the subject of bacteria, showing where they hide and how they are capable of multiplying in record time. Every day we are in contact with billions of bacteria. They are in the air, in food, in water, in our own body… we are surrounded by them. A […]
RTVE. Escarabajo Verde: «The perfect storm»
Human beings and the environment face the global threat of antibiotic-resistant bacteria. By 2050, there could be more deaths from infections than from cancer, and experts around the world are racing to figure out how to curb these “superbugs”. The Escarabajo Verde team investigates what lies behind this crisis and what its relationship with the […]
